On June 4, the anniversary ceremony of the All-Russian Open Competition for Pharmaceutical Market Professionals - Platinum Ounce 2019 - was held in an online format. Platinum Ounce is one of the honored professional competitions of the Russian pharmaceutical market. This year, the contest celebrated its 20th anniversary.
NANOLEK hit the shortlist and became a finalist in two nominations: "Vector of the Year" sub nomination "Project of the Year" Business Project (for the creation of a joint venture Invak with the Chumakov Scientific Center) and "Deal of the Year" (for exiting profile company - "Rusnano").
NANOLEK became the winner in the nomination "Vector of the Year" sub nomination "Project of the Year" Business Project and received an award for the creation of a small investment enterpriseInvak with the Chumakov Scientific Center, which will produce a full-cycle vaccine for immunization of the population of the Russian Federation under the NVS. The first project of the SIE Invak became the production of an entirely domestic polio vaccine, which was submitted for registration in April 2020.
The registration of the vaccine will make it possible to uninterruptedly provide citizens of the Russian Federation with a highly effective and safe vaccine, which is included in the list of the National Vaccination Schedule (NVS). The partnership of the Federal State Budgetary Institution for Health and Social Development named after M.P. Chumakov of the RAS and Nanolek LLC - a successful example of a public-private business to bring promising domestic developments to the market.
Maxim Stetsyuk, Executive Director of NANOLEK:
"On behalf of NANOLEK, I thank the jury and everyone who voted for the high appreciation of the activities of our company. We are pleased to receive the Platinum Ounce Award as a symbol of recognition of our team's merits. NANOLEK hit the list of backbone companies of the Ministry of Industry and Trade. Therefore, we did not stop our work even for a minute, even in these difficult conditions. SIE Invak may become a new model of a public-private partnership to market promising domestic developments. The project provides for the construction of additional production facilities as part of the biotechnological immunobiological research, and educational center's development in the Kirov Region named Biopolis. Both organizations are the participants thereof. I congratulate our company's staff for the next breakthrough in the history of modern pharmaceuticals and urge all companies to pay attention to talented young people, young scientists whom we, by our example, can motivate for discoveries!"
